Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG
Peter Mollee(The University of Queensland), Murielle Roussel(Centre Hospitalier Universitaire de Limoges), P. Morel(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Jill Corre(Institut universitaire du cancer de Toulouse Oncopole), Virginie Pascal(Centre National de la Recherche Scientifique), Salomon Manier(Université de Lille), Cécile Leyronnas, Éstelle Desport(Centre Hospitalier Universitaire de Poitiers), Caroline Jacquet(Délégation Centre-Est), Sébastien Bender(Centre National de la Recherche Scientifique), Guillaume Olombel(Centre Hospitalier Universitaire de Limoges), Noemi Horvath(South Australia Pathology), Margaret Macro(Hôpital Cochin), Laure Vincent(Centre Hospitalier Universitaire de Montpellier), Frank Bridoux(Université de Poitiers), Antoine Huart, Kentin Queru(Centre Hospitalier Universitaire de Limoges), Olga Mortona(Austin Hospital), M Hasib Sidiqi(Curtin University)
Cited by 3
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
|Journal of Clinical Oncology|2012|965
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695